Democritus University of Thrace (DUTH)
Αντιμετώπιση ασθενών με χαμηλή καρδιακή παροχή που υποβάλλονται σε εγχειρήσεις καρδιάς με τη χρήση συσκευής υποβοήθησης της αριστερής κοιλίας διαδερμικής τοποθέτησης
Abstract
dc:descriptionBackground. Temporary ventricular assist devices (VADs) are used in 0.2%-1.2% of all cardiac surgical cases. The hospital discharge rate with temporary VADs as “bridge to recovery” in the post-cardiotomy setting remains low (20%-60%). This study evaluates a recently developed VAD (TandemHeart pVAD, Cardiac Assist, Pittsburgh, PA) in this setting. Patients and Methods. Between August 2001 and August 2004, 14 patients (0.61% of all cardiac surgical cases) were supported by VADs. Eleven of them underwent insertion of the TandemHeart. They were all male, with a mean age of 66.6 years (range: 48-87), a mean LVEF of 26.5%±14.34% (range:10-55%), a mean Euroscore of 10,88±3,44 (range:6- 17). In 7 out of 11 patients acute heart failure occurred as preoperative or intraoperative decompensation of preexisting end stage chronic heart failure. The mean LVEF in this group was 18.57%±5.5% (range: 10-25%). Five of them underwent CABG and endoventriculoplasty procedures, one AVR and undersized mitral annuloplasty, and one Redo MVR of a thrombosed prosthetic valve. Four out of the 11 patients with acute heart failure due to acute coronary syndromes, underwent GABG as salvage (n=2) or as emergency (n=2) procedure. In all patients with acute ischemia and in one patient with preexisting heart failure TandemHeart insertion was preceded by IABP insertion. The major indication for pVAD insertion was failure to wean from CPB (9 patients, intraoperative insertion by “open percutaneous technique”, or by direct cannulation). Other indications were preoperative decompensation of chronic heart failure (1 patient, preoperative percutaneous insertion) and postcardiotomy sudden cardiac arrest (1 patient, postoperative direct insertion). Results. The mean duration of support was 88.04±98.39 hours (range: 0.5-264 hours, median: 41 hours). The mean pump flow was 3.09±1.06L/min (range: 2.1-6 L/min). Eight of 11 patients were successfully weaned (72.72%) from the device and six of 11 patients were discharged from the hospital (54.54%). The major complication was bleeding, observed mainly in patients receiving antiplatelet treatment preoperatively. No device malfunctioning was noted. Survival in one and four years was 45.45% and 36.36% respectively. All survivors are in NYHA functional class I or II. Conclusions. The TandemHeart pVAD appeared to be safe and effective in a cardiac surgical population. Support led to successful weaning from CPB, in patients that would have probably died without assistance, resuscitation from refractory postoperative cardiac arrest, and preoperative hemodynamic stabilization in acutely decompensated chronic heart failure. Device application was effective, with high weaning rate and satisfactory early and long-term survival.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2006
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Πίτσης, Αντώνιος
- Pitsis, Antonios
Subjects
dc:subject × 9Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17554